OSCOTEC INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30,200 KRW | -2.74% |
|
+5.04% | +31.02% |
| Sales 2024 * | 44B 31.94M | Sales 2025 * | 69.5B 50.46M | Capitalization | 1,153B 837M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 24.1 x |
| Net cash position 2024 * | 93B 67.52M | Net cash position 2025 * | 128B 92.56M | EV / Sales 2025 * | 14.8 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 54 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.6% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.74% | ||
| 1 week | +5.04% | ||
| Current month | +9.42% | ||
| 1 month | +2.55% | ||
| 3 months | +50.25% | ||
| 6 months | +56.88% | ||
| Current year | +31.02% |
1 week
28 200.00
31 500.00
1 month
25 100.0031 500.00
Current year
18 540.0031 500.00
1 year
18 000.0036 000.00
3 years
15 850.0042 900.00
5 years
14 900.0071 500.00
10 years
1 450.0071 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Tae-Young Yun
CEO | Chief Executive Officer | 61 | - |
Jeong-Keun Kim
CEO | Chief Executive Officer | 64 | 98-12-07 |
Yoon-Tae Kim
CTO | Chief Tech/Sci/R&D Officer | 61 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jeong-Keun Kim
CEO | Chief Executive Officer | 64 | 98-12-07 |
Sang-Hyeon Lee
BRD | Director/Board Member | 51 | 99-08-31 |
Tae-Young Yun
CEO | Chief Executive Officer | 61 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +0.16% | - | |
| 0.00% | 34 M€ | +2.22% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 30,200 | -2.74% | 291,038 |
| 24-04-24 | 31,050 | -0.48% | 426,083 |
| 24-04-23 | 31,200 | +5.76% | 789,780 |
| 24-04-22 | 29,500 | +5.17% | 548,457 |
| 24-04-19 | 28,050 | -2.43% | 214,497 |
End-of-day quote Korea S.E., April 24, 2024
More quotes
Oscotec Inc.,Ltd is a Korea-based company mainly engaged in the manufacture of functional medical materials and related products. The Company operates its business through three divisions: new medicines division, functional material products division and dental bone graft division. Its new medicines division provides osteoporosis drugs, arthritis drugs and periodontal disease drugs. Its functional material products division provides functional materials and food used for promoting bone growth and periodontal health. Its dental bone graft division provides bone graft materials, membranes and centrifuges. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
30,200
KRW
Average target price
46,500
KRW
Spread / Average Target
+53.97%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +31.02% | 840M | |
| +4.86% | 69.91B | |
| +10.97% | 9.03B | |
| -17.03% | 4.75B | |
| +37.51% | 4.31B | |
| +3.92% | 3.88B | |
| +15.86% | 2.37B | |
| -24.13% | 2.26B | |
| -29.70% | 2.2B | |
| +9.09% | 1.98B |
- Stock Market
- Equities
- A039200 Stock
